As part of the agreement, Sanofi has prepaid €60 million and will devote more resources to further development. December 3, 2018 (London time) — Takeda Pharmaceutical Company Limited (TSE: 4502) (the “Company or “Takeda”) announces that today, December 3, 2018 (London time), it has entered into a loan agreement with Japan Bank for International Cooperation (“JBIC”) for a total capital amount of up to $3,700,000,000 (the “JBIC Loan”). The JBIC loan will finance a portion of the funds required to acquire Shire plc (“Shire”) (the “Acquisition”) and will reduce obligations under the 364-day bridge credit agreement entered into in connection with the Acquisition on May 8, 2018 (as amended on June 8, 2018 and June 26, 2018). October 2018) (the “Bridge Credit Agreement”). We are pleased to have received this loan from JBIC, an organization that promotes the maintenance and strengthening of the international competitiveness of japanese industry,” said Costa Saroukos, Chief Financial Officer of Takeda. “This marks the completion of the planned refinancing program for our bridge facility at an overall very satisfactory mixed interest rate for the various components of the refinancing, which we believe supports our intention to maintain our established dividend policy and investment grade rating. We believe that JBIC`s participation in the financing of the acquisition further reinforces our commitment, our transformation into a global biopharmaceutical market leader headquartered in Japan.In pursuant to Rule 26 of the City`s Code on Takeovers and Mergers, a copy of the JBIC loan will be posted on Takeda`s website and may be published no later than www.takeda.com/investors/offer-for-shire 12 noon (time of London) on the business day following the date of this Announcement. Please note that the acquisition remains subject to certain conditions, including the approval of the shareholders of both companies. Takeda (Investor Relations) Takashi [email protected] 3 3278 2306 Tsuyoshi [email protected] 1 617 551 2933 In accordance with Rule 26 of the Municipal Code of Acquisitions and Mergers, it publishes a copy of the JBIC loan on Takeda`s website and is accessible from www.takeda.com/investors/offer-for-shire to 12:00 .m at the latest.
(London time) on the business day following the announcement. Please note that the acquisition remains subject to certain conditions, including the approval of the shareholders of both companies. Takeda (Media – Japan) Kazumi [email protected] 3 3278 2095 Takeda (Media – outside Japan) Elissa [email protected] 1 312 285 3203. “Working with world-class drug discovery partners such as Evotec is critical to our transformative drug discovery and development model,” said Steve Hitchcock, global head of research at Takeda. “Takeda has been working with Evotec for a long time and is convinced of Evotec`s capabilities.” Takeda retains the drug for Shire`s gut disease, as the EU has waived the deal`s requirements, shares have fallen about 20% since the deal was first confirmed in April, but rose 2% on Tuesday after the deal was confirmed in a statement. . . . Takeda said the acquisition offers an increased geographic presence and position in Japan and the United States. The company will be able to supply approximately 80 countries or regions.
The company`s research and development focuses on oncology, gastroenterology (GI), neuroscience and rare diseases, as well as plasma-based therapies (PDTs) and vaccines. . While Japan`s Fair Trade Commission approved the deal last October, the British court sanctioned it on October 3. January of this year. Takeda shareholders approved the deal last month. Takeda Pharmaceutical, headquartered in Japan, has officially completed the acquisition of Shire`s UK employees for a total of $62 billion. Takeda is one of the ten largest pharmaceutical companies in the world. .
If two or more persons act jointly on the basis of a formal or informal agreement to acquire or control a holding in relevant securities of an offeror company or a securities provider, they shall be considered as a single person within the meaning of Rule 8.3. About Takeda Pharmaceutical Company Takeda Pharmaceutical Company Limited (TSE: 4502) is a global research and development-driven pharmaceutical company dedicated to improving health and a better future for patients by translating science into life-changing medicines. Takeda focuses its research and development efforts on oncology, gastroenterological and neuroscientific therapies and vaccines. Takeda conducts research and development both internally and with partners to stay on the cutting edge of innovation. Innovative products, particularly in oncology and gastroenterology, as well as Takeda`s presence in emerging markets, are currently driving Takeda`s growth. Approximately 30,000 Takeda employees are committed to improving patients` quality of life and work with Takeda`s healthcare partners in more than 70 countries. For more information, see www.takeda.com/newsroom/. Publication on the Website In accordance with Rule 26.1 of the Code, a copy of this notice (subject to certain restrictions for persons residing in restricted jurisdictions) will be made available on Takeda`s website in www.takeda.com/investors/offer-for-shire no later than 12:00.m (London time) on the business day following the date of this announcement. The content of the website mentioned in this statement is not part of this advertisement and is not part of this advertisement. Media and Investor Contacts:Takeda (Investor Relations)Takashi [email protected]+81 3 3278 2306Takeda (Media – in Japan)Kazumi [email protected]+81 3 3278 2095Takeda (Media – outside Japan)Elissa [email protected]+1 312 285 3203Tsuyoshi [email protected]+1 617 551 2933About Takeda Pharmaceutical CompanyTakeda Pharmaceutical Company Limited (TSE: 4502) is a global company focused on research and The pharmaceutical company is committed to providing patients with better health and a better future by turning science into life-changing medicines.
Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience, as well as vaccines. Takeda conducts R&D activities both internally and with partners to stay at the forefront of innovation. Innovative products, particularly in oncology and gastroenterology, as well as Takeda`s presence in emerging markets, are currently driving Takeda`s growth. Approximately 30,000 Takeda employees are committed to improving patients` quality of life and work with Takeda`s healthcare partners in more than 70 countries. For more information, please see www.takeda.com/newsroom/.Important`announcementThis announcement is not intended to be announced and is not part of an offer, solicitation or solicitation of an offer to buy, acquire, subscribe, sell or dispose of any securities, whether as a result of such announcement or otherwise. Distribution of this listing in jurisdictions outside the UK or Japan may be restricted by law or regulation, and therefore anyone who comes into possession of this listing must inform themselves of and comply with these restrictions. Failure to comply with these restrictions may constitute a violation of the securities laws or regulations of that relevant jurisdiction. Publication on the Website In accordance with Rule 26.1 of the Code, a copy of this notice (subject to certain restrictions relating to persons residing in restricted jurisdictions) will be made available on Takeda`s website under www.takeda.com/investors/offer-for-shire no later than 12 noon (London time) on the business day following the date of this announcement.
The website content mentioned in this announcement is not part of this announcement and is not part of this announcement. Code Disclosure Requirements Pursuant to Rule 8.3(a) of the Code, any person interested in 1% or more of a relevant class of securities of a target company or stock exchange provider (which is a supplier other than a supplier for which it has been announced that its offer is or is likely, b. exclusively in cash) must, after the beginning of the offer period and, if later, after the announcement in which a stock exchange provider is first identified, make a disclosure of the opening position. .